MorphoSys AG — Interim / Quarterly Report 2007

Oct 2, 2007

brings disease-specific expertise		" Partner provides target, initiates program,
" Responsibilities	MOR	Partner
Lead generation	"	"
Optimization	"
Development		"
Marketing		"
" Programs exclusive on "per target" basis

Financial Growth
In EUR millions	Guidance 2007	2006	2005
Revenues
Segment Therapeutic Antibodies	2/3 of total revenues	34.7	29.1
Segment AbD	1/3 of total revenues	18.3	4.3
Total Revenues	60 - 65	53.0	33.5*
Total Operating Expenses	-	46.9	27.3
Profit from Operations	7 - 10	6.2*	6.2

Profit & Loss Statement (Group) H1 2007
In EUR millions	H1 2007	H1 2006
Revenues	28.6	26.5
Cost of Goods Sold	4.2	4.0
R&D Expenses	10.5	7.9
S,G&A Expenses	10.5	9.1
Total Operating Expenses	25.1*	21.0
Profit from Operations	3.5	5.6*
Non-Operating Income/(Expenses)	0.2	(0.1)
Profit Before Taxes	3.7	5.4*
Income Tax Expense	1.7	0.9
Net Profit	2.0	4.5
Earnings per Share (diluted) in EUR	0.29	0.70

In EUR millions	06/30/2007	12/31/2006
Assets
Cash, Cash Equivalents & Marketable Securities	102.1	66.0
Other Current Assets	13.6	10.1
Total Non-Current Assets	49.8	51.7
Total Assets	165.5	127.8
Liabilities
Total Current Liabilities	17.6	18.3
Total Non-Current Liabilities	12.5	9.5
Total Shareholders' Equity	135.4	100.1
Total Liabilities	165.5	127.8*